ITEMS IN AFP WITH KEYWORD:
Coronary Artery Disease
In patients with stable angina and severe coronary artery disease (CAD), PCI plus optimal medical treatment does not improve exercise tolerance or angina more than sham PCI plus optimal medical treatment.
What is the effect of omega-3 fatty acid supplementation on cardiovascular outcomes?
Treatment of stable coronary artery disease involves risk factor management, antiplatelet therapy, and antianginal medications. Treatment of comorbidities should be optimized to reduce cardiovascular risk. This article includes a management algorithm and a stepwise approach for antiplatelet therapy.
Nov 1, 2017 Issue
Statins in Persons at Low Risk of Cardiovascular Disease [Medicine by the Numbers]
Despite the small reductions in nonfatal heart attacks and strokes, statins were not associated with a reduction in serious illness overall
Oct 1, 2017 Issue
Prolonged Dual Antiplatelet Therapy After MI Reduces Major Adverse Cardiac Events [Medicine by the Numbers]
In patients who are stable one year post-MI, prolonged use of dual antiplatelet therapy may be an effective treatment to decrease major cardiac events and cardiovascular mortality.
Find out how to use exercise stress testing for risk stratification before surgery, which patients can be evaluated with testing alone, and which patients benefit from adjunctive imaging.
We are now flush with data about the effects of niacin in patients with elevated cholesterol levels. Despite its ability to raise high-density lipoprotein (HDL) serum cholesterol levels, it does not add additional mortality or morbidity benefit to statin treatment. Patients with diabetes mellitus ma...
Get the latest recommendations on when to discontinue antiplatelet therapy, beta blockers, statins, clonidine, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers before surgery.
Management of acute myocardial infarction begins with antiplatelet therapy and anticoagulation therapy, among other medications as appropriate. Learn which reperfusion strategies are recommended for patients with ST elevation myocardial infarction and non–ST elevation acute coronary syndrome.